64XBIO Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 15

64XBIO General Information

Description

Developer of a mammalian cell line discovery platform designed to enhance the design of cell lines for biomanufacturing and therapeutics. The company's platform helps to bring cell and gene therapies to patients effectively and provides purpose-built genetically engineered cell lines for the efficiency of viral vector production, enabling pharmaceutical and biotechnology companies to improve manufacturing capacity and reduce manufacturing costs.

Contact Information

Website
www.64xbio.com
Formerly Known As
64-X
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1000 Marina Boulevard
  • Suite 100
  • Brisbane, CA 94005
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1000 Marina Boulevard
  • Suite 100
  • Brisbane, CA 94005
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

64XBIO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 29-Apr-2025 Completed Generating Revenue
3. Later Stage VC (Series A) 19-Jan-2022 Completed Generating Revenue
2. Early Stage VC (Series A) 18-Apr-2019 $4.38M $4.5M Completed Generating Revenue
1. Accelerator/Incubator 22-Aug-2018 $120K $120K Completed Generating Revenue
To view 64XBIO’s complete valuation and funding history, request access »

64XBIO Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A-2
Series A-5
Series A-4 245,857 $0.000100 $7.24 $7.24 1x $7.24 6.19%
Series A-3 331,493 $0.000100 $4.83 $4.83 1x $4.83 8.35%
To view 64XBIO’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

64XBIO Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a mammalian cell line discovery platform designed to enhance the design of cell lines for biomanufacturing
Drug Discovery
Brisbane, CA
22 As of 2026

Menlo Park, CA
 

Bedford, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

64XBIO Competitors (3)

One of 64XBIO’s 3 competitors is Hexagon Bio, a Venture Capital-Backed company based in Menlo Park, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hexagon Bio Venture Capital-Backed Menlo Park, CA
Conagen Corporate Backed or Acquired Bedford, MA
Codexis Formerly VC-backed Redwood City, CA
You’re viewing 3 of 3 competitors. Get the full list »

64XBIO Patents

64XBIO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024373384-A1 Production technologies Pending 01-Nov-2023
EP-4802088-A1 Production technologies Pending 01-Nov-2023
WO-2025096931-A1 Production technologies Inactive 01-Nov-2023
AU-2023228817-A1 Insect cells and methods for engineering the same Pending 01-Mar-2022
EP-4486902-A1 Insect cells and methods for engineering the same Pending 01-Mar-2022 C12N15/86
To view 64XBIO’s complete patent history, request access »

64XBIO Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

64XBIO Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Charles River Incubator Program Accelerator/Incubator
G Ventures (VC) Venture Capital Minority
Neman Ventures Venture Capital Minority
Angel (individual) Minority
BoxGroup Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

64XBIO FAQs

  • When was 64XBIO founded?

    64XBIO was founded in 2017.

  • Where is 64XBIO headquartered?

    64XBIO is headquartered in Brisbane, CA.

  • What is the size of 64XBIO?

    64XBIO has 22 total employees.

  • What industry is 64XBIO in?

    64XBIO’s primary industry is Drug Discovery.

  • Is 64XBIO a private or public company?

    64XBIO is a Private company.

  • What is 64XBIO’s current revenue?

    The current revenue for 64XBIO is .

  • How much funding has 64XBIO raised over time?

    64XBIO has raised $59.5M.

  • Who are 64XBIO’s investors?

    Charles River Incubator Program, G Ventures (VC), Neman Ventures, , and BoxGroup are 5 of 15 investors who have invested in 64XBIO.

  • Who are 64XBIO’s competitors?

    Hexagon Bio, Conagen, and Codexis are competitors of 64XBIO.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process